State Street’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-65,867
| Closed | -$10.6K | – | 4341 |
|
|
2024
Q4 | $10.6K | Hold |
65,867
| – | – | ﹤0.01% | 4276 |
|
|
2024
Q3 | $15.2K | Hold |
65,867
| – | – | ﹤0.01% | 4243 |
|
|
2024
Q2 | $35.8K | Hold |
65,867
| – | – | ﹤0.01% | 4202 |
|
|
2024
Q1 | $67.2K | Hold |
65,867
| – | – | ﹤0.01% | 4107 |
|
|
2023
Q4 | $37.5K | Hold |
65,867
| – | – | ﹤0.01% | 4250 |
|
|
2023
Q3 | $68.5K | Hold |
65,867
| – | – | ﹤0.01% | 4204 |
|
|
2023
Q2 | $92.9K | Hold |
65,867
| – | – | ﹤0.01% | 4261 |
|
|
2023
Q1 | $105K | Hold |
65,867
| – | – | ﹤0.01% | 4310 |
|
|
2022
Q4 | $96.2K | Buy |
65,867
+6,800
| +12% | +$19.9K | ﹤0.01% | 4379 |
|
|
2022
Q3 | $252K | Hold |
59,067
| – | – | ﹤0.01% | 4035 |
|
|
2022
Q2 | $229K | Sell |
59,067
-529,536
| -90% | -$1.51M | ﹤0.01% | 4135 |
|
|
2022
Q1 | $2.8M | Buy |
588,603
+13,514
| +2% | +$40.7K | ﹤0.01% | 3438 |
|
|
2021
Q4 | $2.1M | Sell |
575,089
-2,463
| -0.4% | -$13.1K | ﹤0.01% | 3617 |
|
|
2021
Q3 | $4.63M | Buy |
577,552
+93,330
| +19% | +$920K | ﹤0.01% | 3278 |
|
|
2021
Q2 | $5.49M | Buy |
+484,222
| New | +$4.86M | ﹤0.01% | 3197 |
|
|
2020
Q3 | – | Sell |
-349
| Closed | -$3K | – | 3872 |
|
|
2020
Q2 | $3K | Hold |
349
| – | – | ﹤0.01% | 3808 |
|
|
2020
Q1 | $5K | Hold |
349
| – | – | ﹤0.01% | 3747 |
|
|
2019
Q4 | $4K | Hold |
349
| – | – | ﹤0.01% | 3803 |
|
|
2019
Q3 | $9K | Hold |
349
| – | – | ﹤0.01% | 3790 |
|
|
2019
Q2 | $9K | Hold |
349
| – | – | ﹤0.01% | 3797 |
|
|
2019
Q1 | $15K | Hold |
349
| – | – | ﹤0.01% | 3715 |
|
|
2018
Q4 | $5K | Hold |
349
| – | – | ﹤0.01% | 3751 |
|
|
2018
Q3 | $24K | Sell |
349
-67
| -16% | -$5.09K | ﹤0.01% | 3727 |
|
|
2018
Q2 | $30K | Sell |
416
-62
| -13% | -$5.52K | ﹤0.01% | 3709 |
|
|
2018
Q1 | $46K | Buy |
+478
| New | +$82K | ﹤0.01% | 3661 |
|
|
2016
Q3 | – | Sell |
-133
| Closed | -$15K | – | 3614 |
|
|
2016
Q2 | $15K | Hold |
133
| – | – | ﹤0.01% | 3671 |
|
|
2016
Q1 | $15K | Hold |
133
| – | – | ﹤0.01% | 3679 |
|
|
2015
Q4 | $25K | Hold |
133
| – | – | ﹤0.01% | 3643 |
|
|
2015
Q3 | $23K | Sell |
133
-8
| -6% | -$2.89K | ﹤0.01% | 3647 |
|
|
2015
Q2 | $89K | Sell |
141
-3,367
| -96% | -$1.79M | ﹤0.01% | 3547 |
|
|
2015
Q1 | $1.81M | Buy |
3,508
+441
| +14% | +$222K | ﹤0.01% | 3059 |
|
|
2014
Q4 | $1.64M | Buy |
3,067
+464
| +18% | +$209K | ﹤0.01% | 3117 |
|
|
2014
Q3 | $3.9M | Buy |
2,603
+295
| +13% | +$427K | ﹤0.01% | 2668 |
|
|
2014
Q2 | $3.16M | Buy |
2,308
+273
| +13% | +$317K | ﹤0.01% | 2843 |
|
|
2014
Q1 | $2.83M | Sell |
2,035
-51
| -2% | -$59.3K | ﹤0.01% | 2886 |
|
|
2013
Q4 | $2.08M | Sell |
2,086
-2
| -0.1% | -$2.07K | ﹤0.01% | 3053 |
|
|
2013
Q3 | $2.17M | Buy |
2,088
+59
| +3% | +$63K | ﹤0.01% | 2995 |
|
|
2013
Q2 | $2.22M | Buy |
+2,029
| New | +$2.26M | ﹤0.01% | 2926 |
|
Other funds holding VIRX
XT
UCFA
WA
BBA
RM
State Street's VIRX Position: Q1 2025 in Review
State Street sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 65,867 shares — an estimated $10.6K sold.
State Street first reported a position in VIRX in Q2 2013 and held it in 38 quarters. The position peaked at $5.49M in Q2 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.
- State Street reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- State Street sold 65,867 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $10.6K.
- State Street first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 38 quarters.
- State Street's Viracta Therapeutics, Inc. Common Stock position peaked at $5.49M in Q2 2021.
- 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.
Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.